ReviewCentral European journal of urology2025
Safety and efficacy of tranexamic acid in radical cystectomy: a systematic review and meta-analysis.
Review in Central European journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Perioperative blood transfusion (BT) is often required in radical cystectomy (RC) due to significant blood loss. Tranexamic acid (TXA), an antifibrinolytic agent, reduces bleeding, but concerns about thromboembolic risks persist. This systematic review and meta-analysis evaluate TXA's efficacy and safety in RC. Material and methods: A systematic search was conducted in PubMed, Embase, and Cochrane Central databases. Randomized controlled trials (RCTs) and retrospective studies comparing TXA versus controls in RC were included. Primary outcomes were perioperative, intraoperative, and postoperative BT rates. Secondary outcomes included estimated blood loss (EBL) and thromboembolic events (PROSPERO; CRD420251013502). Results: Four studies totaling 1,656 patients were included. TXA significantly reduced perioperative transfusion rates (OR = 0.40; 95% CI: 0.30-0.51; p < 0.00001). However, intraoperative (OR = 0.87; 95% CI: 0.50-1.52; p = 0.63) and postoperative transfusion rates (OR = 0.51; 95% CI: 0.21-1.23; p = 0.13) were not significantly different. No significant difference was found in EBL (MD = -9.31; 95% CI: from -82.50 to 63.87; p = 0.80). Safety analysis showed no increased risk of deep vein thrombosis (OR = 1.14; 95% CI: 0.54-2.41; p = 0.72) or pulmonary embolism (OR = 1.49; 95% CI: 0.69-3.24; p = 0.31). Conclusions: TXA reduces perioperative transfusion needs in RC without significantly affecting intraoperative or postoperative transfusion rates, EBL, or thromboembolic risk. Further RCTs are needed to optimize TXA use in RC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.